Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C
Daito, K.; Suou, T.; Kawasaki, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 53 Suppl(Pt 1): 981-985
1995
ISSN/ISBN: 0047-1852 PMID: 7563914 Document Number: 451419
Document emailed within 1 workday
Related Documents
Daito, K.; Suou, T.; Kawasaki, H. 1994: Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon Research Communications in Chemical Pathology and Pharmacology 83(3): 303-316Ostlund, L.; Einhorn, S.; Robèrt, K.H. 1986: Induction of 2',5'-oligoadenylate synthetase and blast transformation in primary chronic lymphocytic leukemia cells following exposure to interferon in vitro Cancer Research 46(4 Part 2): 2160-2163
Bonnevie-Nielsen, V. 1990: Interferon, oligoadenylate synthetase and oligoadenine nucleotide--a cell biological triad Ugeskrift for Laeger 152(16): 1140-1143
Fraioli, M.; Wu, J.M. 1989: Differential induction of 2',5'-oligoadenylate synthetase by IFN-beta ser and IFN-alpha 2 in serum-supplemented and serum-free HL-60 leukemic cell cultures Journal of Biological Regulators and Homeostatic Agents 3(3): 112-117
Levitan, B.N.; Astakhin, A.V.; Chishieva, E.M.; Afanas'ev, S.S. 2004: Serum concentration and antiviral activity of interferon alpha in chronic hepatitis and liver cirrhosis Voenno-Meditsinskii Zhurnal 325(2): 60
Hrycewycz, N.; Sandres, K.; Barange, K.; Pascal, J.P.; Izopet, J.; Payen, J.L. 2001: Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C Gastroenterologie Clinique et Biologique 25(11): 1041-1042
Lang, M.H.; Lodemann, E.; Holzmann, H.; Heimbrodt, M. 1988: Serum interferon level and (2'-5')-oligo(A) synthetase activity in pityriasis rosea, basalioma, melanoma and molluscum contagiosum Zeitschrift für Hautkrankheiten 63(12): 1028-1036
Liu, D.K.; Owens, G.F.; Feil, P.D. 1986: 2',5'-oligoadenylate synthetase activity in human mammary tumors and its potential correlation with tumor growth or hormonal responsiveness Cancer Research 46(12 Part 1): 6207-6210
Castañeda, C.; García, E.; Grá, B.; Nodarse-Cuní, H.; García, W.; Andrade, M.; Martínez, G.; Trujillo, M.ía.; Soto, G.; Amoroto, M.é; Viada, C.; López-Saura, P. 2002: Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B Acta Gastroenterologica Latinoamericana 32(1): 35-42
Moulin, V.; Harzic, M.; Doll, J.; Dubeaux, B.; Ghnassia, J.C.; Andrieu, J. 1996: Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C Pathologie-Biologie 44(5): 468-472
Musch, E.; Högemann, B.; Gerritzen, A.; Fischer, H.P.; Wiese, M.; Kruis, W.; Malek, M.; Gugler, R.; Schmidt, G.; Huchzermeyer, H.; Gerlach, U.; Dengler, H.J.; Sauerbruch, T. 1998: Phase Ii clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B Hepato-Gastroenterology 45(24): 2282-2294
Lobello, S.; Lorenzoni, U.; Vian, A.; Floreani, A.; Brunetto, M.R.; Chiaramonte, M. 1998: Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring Journal of Viral Hepatitis 5(1): 61-66
Sokawa, Y. 1981: (2'-5') oligoadenylate and its synthetase Seikagaku. Journal of Japanese Biochemical Society 53(11): 1234-1238
Kaneko, S.; Sakai, A. 2004: 2' 5'-oligoadenylate synthetase (2-5AS) Nihon Rinsho. Japanese Journal of Clinical Medicine 62(Suppl 12): 812-814
Baba, T.; Makino, R.; Shibata, M.; Harada, E.; Mitamura, K. 1997: Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 55(3): 625-630
Teuber, G.; Dienes, H.P.; Meyer zum Büschenfelde, K.H.; Gerken, G. 1995: Hepatitis B virus superinfection in a patient with chronic hepatitis C receiving alpha-interferon treatment Hepato-Gastroenterology 42(2): 189-191
Tsuji, H.; Murai, K.; Akagi, K.; Fujishima, M. 1990: Effects of recombinant leukocyte interferon on ribonuclease activities in serum in chronic hepatitis B Clinical Chemistry 36(6): 913-916
Alagiozian-Angelova, V.; Alagiozian, D.; Lyutakova, E.; Grigorov, L. 1998: Endogenous serum interferon-alpha in patients with chronic hepatitis B virus infection Folia Medica 40(3): 71-75
Ho, A.D.; Klotzbücher, A.; Gross, A.; Dietz, G.; Mestan, J.; Jakobsen, H.; Hunstein, W. 1992: Induction of intracellular and plasma 2',5'-oligoadenylate synthetase by pentostatin Leukemia 6(3): 209-214
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72